85
Participants
Start Date
November 30, 2004
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
custirsen sodium
Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
New York Oncology Hematology, Albany
Cancer Centers of the Carolinas, Greenville
Mary Crowley Medical Research Center, Dallas
LAC-USC Medical Center, Los Angeles
University of Southern California Norris, Los Angeles
Oregon Health and Science University, Portland
Tom Baker Cancer Centre, Calgary
BC Cancer Agency, Fraser Valley Centre, Surrey
BC Cancer Agency, Vancouver Center, Vancouver
Dr. H. Bliss Murphy Cancer Center, St. John's
Royal Victoria Hospital of Barrie, Barrie
London Regional Cancer Centre, London
Ottawa Hospital, Ottawa
Toronto Sunnybrook Regional Cancer Center, Toronto
Hopital Laval, Ste-Foy
Lead Sponsor
Achieve Life Sciences
INDUSTRY